AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea. A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea. In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022. In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
dct:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
vaccine type |
|
dbp:wikiPageUsesTemplate | |
routes of administration | |
target | |
type |
|
has abstract |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is foaf:primaryTopic of |